Peptides and Cancer: What Patients and Researchers Need to Know

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Some peptides (IGF-1 LR3, GH secretagogues) theoretically promote cancer cell growth and should be avoided by individuals with active cancer or high cancer risk. Other peptides (Thymosin Alpha-1, LL-37) have anti-cancer properties. Careful risk assessment is essential before using any peptide in a cancer context.

The Complex Relationship Between Peptides and Cancer

The relationship between peptide therapy and cancer is nuanced and often misunderstood. Some peptides have theoretical or demonstrated pro-proliferative effects that raise concerns in cancer patients, while others have demonstrated anti-tumor properties. Understanding this distinction is essential for anyone with a personal or family history of cancer who is considering peptide therapy.

Peptides with Potential Pro-Cancer Concerns

IGF-1 and IGF-1 LR3 are potent mitogens (cell growth promoters) that activate the PI3K/Akt/mTOR pathway — one of the most commonly dysregulated pathways in cancer. Epidemiological studies have shown associations between elevated IGF-1 levels and increased risk of several cancers (breast, prostate, colorectal). While this does not mean that therapeutic IGF-1 LR3 causes cancer, individuals with a personal or family history of cancer should avoid this peptide. GH Secretagogues stimulate IGF-1 production, which raises similar concerns to direct IGF-1 administration. The risk is lower than with direct IGF-1 LR3 use (because GH secretagogues work through the body's natural feedback mechanisms and produce physiological rather than supraphysiological IGF-1 levels), but caution is warranted in high-risk individuals. Follistatin 344 by inhibiting myostatin and other TGF-beta family members that have tumor-suppressive properties theoretically could promote cancer progression.

Peptides with Anti-Cancer Properties

Thymosin Alpha-1 has been extensively studied as a cancer adjunct therapy. It enhances anti-tumor immunity, improves response to chemotherapy, and has been shown to improve outcomes in several cancer types. It is one of the few peptides that is actively beneficial in cancer patients. LL-37 has demonstrated direct cytotoxic effects against several cancer cell lines and promotes anti-tumor immune responses. GHK-Cu has shown anti-cancer properties in some studies, including inhibition of cancer cell growth and promotion of DNA repair.

Practical Guidance

For individuals with active cancer: avoid IGF-1 LR3, GH secretagogues, and follistatin 344. Consider Thymosin Alpha-1 as an adjunct to conventional cancer therapy (under medical supervision). For individuals with a family history of cancer: exercise caution with IGF-1 LR3 and high-dose GH secretagogues. Regular cancer screening is appropriate. For individuals without cancer risk factors: the theoretical concerns about GH secretagogues at physiological doses are not a reason to avoid them, but awareness of the issue is appropriate.